KALA BIO Halts Key Drug Development, Cuts Staff Amid Cash Crunch

TL;DR

**KALA BIO is on life support after its lead drug failed, making it a high-risk bet for any investor hoping for a miraculous turnaround.**

AI Summary

KALA BIO, Inc. reported a net loss of $27.666 million for the nine months ended September 30, 2025, a slight improvement from the $30.336 million loss in the same period of 2024. The company's cash and cash equivalents significantly decreased to $21.096 million as of September 30, 2025, from $51.181 million at December 31, 2024. This substantial cash burn was primarily driven by $27.435 million in cash used in operating activities during the nine months ended September 30, 2025. A major strategic shift occurred on September 29, 2025, when KALA BIO announced that its CHASE Phase 2b clinical trial for KPI-012 in persistent corneal epithelial defect (PCED) failed to meet its primary endpoint and key secondary efficacy endpoints, leading to the cessation of KPI-012 development and a workforce reduction of approximately 51% (19 employees). The company is now actively exploring strategic options to preserve cash, facing a significant increase in current portion of long-term debt to $28.411 million from $10.336 million at December 31, 2024, and a total stockholders' deficit of $(8.665) million.

Why It Matters

This filing signals a critical juncture for KALA BIO, Inc., as the failure of its lead drug candidate, KPI-012, and subsequent workforce reduction, casts serious doubt on its future as a standalone entity. For investors, the significant cash burn and the shift to a stockholders' deficit of $(8.665) million indicate severe financial distress and potential for further dilution or even bankruptcy. Employees face job insecurity, with 51% already laid off. Customers and the broader market will see one less potential treatment for rare ocular diseases, impacting the competitive landscape for ophthalmic therapies. The company's ability to find a viable strategic option will determine its survival.

Risk Assessment

Risk Level: high — The company explicitly stated it 'determined to cease development of KPI-012 and its MSC-S platform and to take steps to preserve cash as the Company explores its strategic options' after the CHASE Phase 2b trial failed to meet its primary endpoint. This, coupled with a significant cash decrease from $51.181 million to $21.096 million and a current portion of long-term debt of $28.411 million exceeding current cash, indicates severe operational and financial challenges.

Analyst Insight

Investors should consider divesting KALA BIO shares due to the cessation of its lead drug program, significant cash burn, and the company's stated need to explore 'strategic options,' which often includes asset sales or bankruptcy. The high debt load relative to cash on hand presents an immediate liquidity risk.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

$25.021M

total Debt

$29.523M

net Income

-$27.666M

eps

-$1.07

gross Margin

N/A

cash Position

$21.096M

revenue Growth

N/A

Key Numbers

• $21.096M — Cash and cash equivalents (Decreased from $51.181M at Dec 31, 2024, indicating significant cash burn.)
• $27.666M — Net loss (For the nine months ended Sept 30, 2025, showing continued unprofitability.)
• $28.411M — Current portion of long-term debt (Increased from $10.336M at Dec 31, 2024, posing a significant short-term liquidity challenge.)
• $(8.665)M — Total stockholders' (deficit) equity (Shifted from $12.332M equity at Dec 31, 2024, indicating negative shareholder value.)
• $27.435M — Net cash used in operating activities (For the nine months ended Sept 30, 2025, highlighting operational cash drain.)
• $1.07 — Net loss per share (Q3 2025) (Compared to $1.93 in Q3 2024, showing a smaller loss per share despite operational challenges.)
• 7,432,925 — Common shares outstanding (As of Sept 30, 2025, up from 6,091,182 at Dec 31, 2024, indicating dilution.)
• $378K — Workforce reduction costs (Incurred during Q3 2025, primarily severance and benefits.)

Key Players & Entities

• KALA BIO, Inc. (company) — registrant
• KPI-012 (product) — lead product candidate for PCED
• CHASE Phase 2b clinical trial (event) — failed to meet primary endpoint
• Combangio, Inc. (company) — acquired company
• Oxford Finance LLC (company) — debt holder mentioned in forward-looking statements
• Alcon Pharmaceuticals Ltd. (company) — potential future milestone payments
• Alcon Visions, LLC (company) — potential future milestone payments
• Nasdaq Capital Market (regulator) — exchange where KALA is listed
• 19 employees (dollar_amount) — number of employees reduced
• 51% (dollar_amount) — percentage of workforce reduction

FAQ

Risk Factors

• Clinical Trial Failure and Strategic Pivot [high — operational]: The failure of the CHASE Phase 2b trial for KPI-012 on September 29, 2025, led to the cessation of its development. This significant setback necessitated a strategic shift and a workforce reduction of approximately 51% (19 employees), impacting future operational capacity and focus.
• Deteriorating Liquidity and Increased Debt [high — financial]: Cash and cash equivalents plummeted to $21.096 million as of September 30, 2025, from $51.181 million at December 31, 2024. Concurrently, the current portion of long-term debt surged to $28.411 million from $10.336 million, creating a significant short-term liquidity challenge.
• Negative Stockholders' Equity [high — financial]: The company now has a total stockholders' deficit of $(8.665) million as of September 30, 2025, a stark contrast to the $12.332 million equity position at December 31, 2024. This indicates a negative value for shareholders and raises concerns about financial solvency.
• Significant Cash Burn from Operations [high — operational]: Operating activities consumed $27.435 million in cash during the first nine months of 2025, underscoring the high cost of operations relative to revenue generation and contributing to the rapid decline in cash reserves.
• Increased Common Shares Outstanding [medium — financial]: The number of common shares outstanding increased from 6,091,182 at December 31, 2024, to 7,432,925 as of September 30, 2025. This dilution may negatively impact existing shareholders' ownership percentage and earnings per share.
• Workforce Reduction [medium — operational]: A workforce reduction of approximately 51% (19 employees) was implemented following the clinical trial failure. While intended to preserve cash, this significantly impacts the company's human capital and operational capabilities.

Industry Context

The biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on substantial funding to advance drug candidates through clinical trials. Success is heavily dependent on clinical trial outcomes and subsequent regulatory approvals, with failures leading to substantial financial write-offs and strategic reorientations.

Regulatory Implications

The failure of KPI-012 in a Phase 2b trial highlights the inherent regulatory risks in drug development. While no new regulatory actions are detailed, the company's pivot away from this candidate means future regulatory pathways will depend on entirely new development programs, which carry their own set of uncertainties and stringent FDA requirements.

What Investors Should Do

1. Monitor cash runway closely.
2. Evaluate the viability of new strategic options.
3. Assess the impact of workforce reduction.
4. Understand the implications of the stockholders' deficit.

Key Dates

• 2025-09-30: End of Q3 2025 — Reporting period for the 10-Q, showing a net loss of $27.666M and cash of $21.096M, with a stockholders' deficit of $(8.665)M.
• 2025-09-29: Announcement of CHASE Phase 2b Trial Failure — KPI-012 failed to meet primary and key secondary endpoints, leading to development cessation and a workforce reduction of 51%.
• 2025-12-31: End of Fiscal Year 2024 — Prior period comparison point for balance sheet items, showing $51.181M in cash and $12.332M in stockholders' equity.

Glossary

Stockholders' deficit

A situation where a company's total liabilities exceed its total assets, resulting in negative equity for shareholders. (KALA BIO currently has a stockholders' deficit of $(8.665) million, indicating negative shareholder value.)

Current portion of long-term debt

The amount of long-term debt that is due within the next year. (This amount has significantly increased to $28.411 million, posing a short-term liquidity challenge for KALA BIO.)

Persistent Corneal Epithelial Defect (PCED)

A medical condition characterized by the failure of the cornea's epithelial cells to heal properly, often leading to vision problems. (This was the indication for KALA BIO's failed drug candidate, KPI-012.)

Net cash used in operating activities

The total cash spent by a company on its core business operations during a specific period. (KALA BIO used $27.435 million in operating activities for the nine months ended September 30, 2025, highlighting its cash burn.)

Accumulated deficit

The cumulative net losses of a company since its inception, less any net gains. (KALA BIO has an accumulated deficit of $(695.586) million as of September 30, 2025, reflecting its history of unprofitability.)

Year-Over-Year Comparison

KALA BIO's financial position has significantly deteriorated compared to December 31, 2024. Cash and cash equivalents have more than halved, dropping from $51.181 million to $21.096 million. The company has shifted from a positive stockholders' equity of $12.332 million to a deficit of $(8.665) million. Furthermore, the current portion of long-term debt has nearly tripled, increasing from $10.336 million to $28.411 million, indicating a substantial increase in short-term financial pressure.

Key Financial Figures

• $0.001 — t Title of each class Common Stock, $0.001 par value per share Trading symbol(s)

Filing Documents

• kala-20250930x10q.htm (10-Q) — 2197KB
• kala-20250930xex10d2.htm (EX-10.2) — 148KB
• kala-20250930xex31d1.htm (EX-31.1) — 15KB
• kala-20250930xex31d2.htm (EX-31.2) — 15KB
• kala-20250930xex32d1.htm (EX-32.1) — 7KB
• kala-20250930xex32d2.htm (EX-32.2) — 7KB
• 0001104659-25-113927.txt ( ) — 8625KB
• kala-20250930.xsd (EX-101.SCH) — 67KB
• kala-20250930_cal.xml (EX-101.CAL) — 54KB
• kala-20250930_def.xml (EX-101.DEF) — 329KB
• kala-20250930_lab.xml (EX-101.LAB) — 545KB
• kala-20250930_pre.xml (EX-101.PRE) — 430KB
• kala-20250930x10q_htm.xml (XML) — 1281KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 5 Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 5 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 5 Condensed Consolidated Statement of Operations and Comprehensive Loss for the three and nine months ended September 30, 2025 and 2024 6 Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the three and nine months ended September 30, 2025 and 2024 7 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 9 Notes to Condensed Consolidated Financial Statements 10 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 30 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 49 Item 4.

Controls and Procedures

Controls and Procedures 50

– OTHER INFORMATION

PART II – OTHER INFORMATION 50 Item 1.

Legal Proceedings

Legal Proceedings 50 Item 1A.

Risk Factors

Risk Factors 50 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 52 Item 5. Other Information 53 Item 6. Exhibits 54

SIGNATURES

SIGNATURES 55 2 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about: our pursuit of strategic options; our plans and expectations regarding our pursuit of strategic options; our ability to obtain additional financing; the possibility of entering bankruptcy or insolvency proceedings; our ability to monetize our assets; our expectations regarding the value or recovery that may be available to our stockholders as part of a bankruptcy process; our ability to continue as a going concern; developments regarding Oxford Finance LLC's foreclosure of our assets; our ability to regain and maintain compliance with the Nasdaq listing standards; the potential benefits and advantages of KPI-012 and KPI-014; our ability to retain our remaining employees, consultants, advisors; our ability to resume research and development activities if we were to execute a strategic transaction or obtain significant additional funding; if we were to resume research and development activities, development efforts for KPI-012 and KPI-014 for potential ocular diseases; our ability to id

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements . KALA BIO, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (In thousands, except share and per share amounts) September 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 21,096 $ 51,181 Prepaid expenses and other current assets 3,178 1,616 Total current assets 24,274 52,797 Non-current assets: Property and equipment, net 603 749 Right-of-use assets — 1,691 Other long-term assets 144 246 Total assets $ 25,021 $ 55,483 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 917 $ 628 Accrued expenses and other current liabilities 2,826 4,975 Deferred grant income — 637 Current portion of lease liabilities 420 380 Current portion of long-term debt 28,411 10,336 Total current liabilities 32,574 16,956 Long-term liabilities: Long-term lease liabilities 1,112 1,434 Long-term debt, net of current portion — 20,102 Long-term contingent consideration — 4,659 Total long-term liabilities 1,112 26,195 Total liabilities 33,686 43,151 Commitments and Contingencies (Note 14) Stockholders' equity: Preferred stock, $ 0.001 par value; 5,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 51,246 shares of Series E Convertible Non-Redeemable Preferred Stock issued and outstanding as of September 30, 2025 and December 31, 2024, 2,928 shares of Series F Convertible Non-Redeemable Preferred Stock issued and outstanding as of September 30, 2025 and December 31, 2024, 10,901 shares of Series G Convertible Non-Redeemable Preferred Stock issued and outstanding as of September 30, 2025 and December 31, 2024, 2,299 and 9,393 shares of Series H Convertible Non-Redeemable Preferred Stock issued and outstanding as of September 30, 2025 and December 31, 2024, 0 and 3,286 shares of Series I Convertible Non-Redeemable Preferred Stock issued and outstanding as of September 30,

View Full Filing

View this 10-Q filing on SEC EDGAR